Litcius/Paper detail

The Research Progress of Direct KRAS G12C Mutation Inhibitors

Ai Li Yang, Min Li, Mingzhi Fang

2021Pathology & Oncology Research15 citationsDOIOpen Access PDF

Abstract

KRAS mutations have long been considered undruggable. However, a series of direct KRAS mutation inhibitors have been developed since the switch II pocket was discovered recently. This review will summarize progress in the development of direct KRAS G12C mutation inhibitors, current relevant drugs under study and challenges that need to be considered in future research.

Topics & Concepts

KRASMutationMutation testingComputational biologyBioinformaticsCancer researchBiologyGeneticsGeneProtein Kinase Regulation and GTPase SignalingReceptor Mechanisms and SignalingPhosphodiesterase function and regulation